159 related articles for article (PubMed ID: 25129986)
1. Carboplatin dosing for adult Japanese patients.
Ando Y; Shimokata T; Yasuda Y; Hasegawa Y
Nagoya J Med Sci; 2014 Feb; 76(1-2):1-9. PubMed ID: 25129986
[TBL] [Abstract][Full Text] [Related]
2. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer.
Shimokata T; Ando Y; Yasuda Y; Hamada A; Kawada K; Saito H; Matsuo S; Kondo M; Imaizumi K; Hasegawa Y
Cancer Sci; 2010 Dec; 101(12):2601-5. PubMed ID: 20860621
[TBL] [Abstract][Full Text] [Related]
4. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
[TBL] [Abstract][Full Text] [Related]
5. Extension of the Calvert formula to patients with severe renal insufficiency.
Oguri T; Shimokata T; Ito I; Yasuda Y; Sassa N; Nishiyama M; Hamada A; Hasegawa Y; Ando Y
Cancer Chemother Pharmacol; 2015 Jul; 76(1):53-9. PubMed ID: 25957958
[TBL] [Abstract][Full Text] [Related]
6. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
Morrow A; Garland C; Yang F; De Luna M; Herrington JD
J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
[TBL] [Abstract][Full Text] [Related]
7. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
[TBL] [Abstract][Full Text] [Related]
8. Flat dosing of carboplatin is justified in adult patients with normal renal function.
Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
[TBL] [Abstract][Full Text] [Related]
9. Adjustment of creatinine clearance improves accuracy of Calvert's formula for carboplatin dosing.
Ando Y; Minami H; Saka H; Ando M; Sakai S; Shimokata K
Br J Cancer; 1997; 76(8):1067-71. PubMed ID: 9376268
[TBL] [Abstract][Full Text] [Related]
10. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
Bretagne M; Jouinot A; Durand JP; Huillard O; Boudou Rouquette P; Tlemsani C; Arrondeau J; Sarfati G; Goldwasser F; Alexandre J
Cancer Chemother Pharmacol; 2017 Jul; 80(1):45-53. PubMed ID: 28508095
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of carboplatin, etoposide and melphalan in children: a re-evaluation of paediatric dosing formulas for carboplatin in patients with normal or mild impairment of renal function.
Duong JK; Veal GJ; Nath CE; Shaw PJ; Errington J; Ladenstein R; Boddy AV
Br J Clin Pharmacol; 2019 Jan; 85(1):136-146. PubMed ID: 30261554
[TBL] [Abstract][Full Text] [Related]
12. The use of the Calvert formula to determine the optimal carboplatin dosage.
van Warmerdam LJ; Rodenhuis S; ten Bokkel Huinink WW; Maes RA; Beijnen JH
J Cancer Res Clin Oncol; 1995; 121(8):478-86. PubMed ID: 7642691
[TBL] [Abstract][Full Text] [Related]
13. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.
Ando M; Minami H; Ando Y; Saka H; Sakai S; Yamamoto M; Sasaki Y; Shimokata K; Hasegawa Y
Clin Cancer Res; 2000 Dec; 6(12):4733-8. PubMed ID: 11156227
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose.
Shord SS; Bressler LR; Radhakrishnan L; Chen N; Villano JL
Ann Pharmacother; 2009 Feb; 43(2):235-41. PubMed ID: 19193580
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
[TBL] [Abstract][Full Text] [Related]
17. Survey of carboplatin dosing strategies in oncology practices.
Blankenship P; Waddell JA
J Am Pharm Assoc (2003); 2013; 53(4):420-2. PubMed ID: 23892816
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
van Warmerdam LJ; Rodenhuis S; ten Bokkel Huinink WW; Maes RA; Beijnen JH
Cancer Chemother Pharmacol; 1996; 37(3):266-70. PubMed ID: 8529288
[TBL] [Abstract][Full Text] [Related]
19. [Clinical evaluation of calculating carboplatin dosage using Japanese equation for estimating GFR for gynecologic cancer].
Kidera Y; Nakao M; Tsubaki M; Yoshinaga M; Kajitani F; Yanae M; Sakano M; Yamazoe Y; Chiba Y; Moriyama K; Nishida S
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1143-8. PubMed ID: 21772099
[TBL] [Abstract][Full Text] [Related]
20. Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function.
Adamson PC; Veal GJ; Womer RB; Meany HJ; Bernhardt MB; Frazier AL; Balis FM
Pediatr Blood Cancer; 2019 Jun; 66(6):e27672. PubMed ID: 30767382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
